Paramount Global Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $4.10 billion. The enterprise value is $4.10 billion.
Important Dates
The last earnings date was Wednesday, August 6, 2025, after market close.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 238.63 million shares outstanding. The number of shares has increased by 5.91% in one year.
| Current Share Class | 238.63M |
| Shares Outstanding | 238.63M |
| Shares Change (YoY) | +5.91% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 1.96% |
| Owned by Institutions (%) | 90.14% |
| Float | 233.86M |
Valuation Ratios
The trailing PE ratio is 20.35 and the forward PE ratio is 23.83.
| PE Ratio | 20.35 |
| Forward PE | 23.83 |
| PS Ratio | 8.59 |
| Forward PS | 9.67 |
| PB Ratio | 10.30 |
| P/TBV Ratio | 10.41 |
| P/FCF Ratio | 62.40 |
| P/OCF Ratio | 53.51 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 25.06, with an EV/FCF ratio of 62.31.
| EV / Earnings | 19.61 |
| EV / Sales | 8.64 |
| EV / EBITDA | 25.06 |
| EV / EBIT | 26.33 |
| EV / FCF | 62.31 |
Financial Position
The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.21.
| Current Ratio | 5.33 |
| Quick Ratio | 2.67 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | 1.27 |
| Interest Coverage | 15.28 |
Financial Efficiency
Return on equity (ROE) is 71.23% and return on invested capital (ROIC) is 23.96%.
| Return on Equity (ROE) | 71.23% |
| Return on Assets (ROA) | 20.81% |
| Return on Invested Capital (ROIC) | 23.96% |
| Return on Capital Employed (ROCE) | 32.19% |
| Revenue Per Employee | $692,225 |
| Profits Per Employee | $305,003 |
| Employee Count | 685 |
| Asset Turnover | 1.01 |
| Inventory Turnover | 1.20 |
Taxes
| Income Tax | -63.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.56% in the last 52 weeks. The beta is 0.38, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | +4.56% |
| 50-Day Moving Average | 18.50 |
| 200-Day Moving Average | 18.79 |
| Relative Strength Index (RSI) | 43.74 |
| Average Volume (20 Days) | 3,567,858 |
Short Selling Information
The latest short interest is 13.74 million, so 5.76% of the outstanding shares have been sold short.
| Short Interest | 13.74M |
| Short Previous Month | 14.47M |
| Short % of Shares Out | 5.76% |
| Short % of Float | 5.87% |
| Short Ratio (days to cover) | 5.53 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $474.17 million and earned $208.93 million in profits. Earnings per share was $0.85.
| Revenue | 474.17M |
| Gross Profit | 251.32M |
| Operating Income | 155.64M |
| Pretax Income | n/a |
| Net Income | 208.93M |
| EBITDA | 163.55M |
| EBIT | 155.64M |
| Earnings Per Share (EPS) | $0.85 |
Full Income StatementBalance Sheet
The company has $90.29 million in cash and $83.83 million in debt, giving a net cash position of $6.46 million or $0.03 per share.
| Cash & Cash Equivalents | 90.29M |
| Total Debt | 83.83M |
| Net Cash | 6.46M |
| Net Cash Per Share | $0.03 |
| Equity (Book Value) | 398.33M |
| Book Value Per Share | 1.67 |
| Working Capital | 324.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $76.71 million and capital expenditures -$10.94 million, giving a free cash flow of $65.77 million.
| Operating Cash Flow | 76.71M |
| Capital Expenditures | -10.94M |
| Free Cash Flow | 65.77M |
| FCF Per Share | $0.28 |
Full Cash Flow StatementMargins
Gross margin is 53.00%, with operating and profit margins of 32.82% and 44.06%.
| Gross Margin | 53.00% |
| Operating Margin | 32.82% |
| Pretax Margin | 30.58% |
| Profit Margin | 44.06% |
| EBITDA Margin | 34.49% |
| EBIT Margin | 32.82% |
| FCF Margin | 13.87% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.91% |
| Shareholder Yield | -5.91% |
| Earnings Yield | 5.09% |
| FCF Yield | 1.60% |
Analyst Forecast
The average price target for ADMA Biologics is $27.67, which is 60.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $27.67 |
| Price Target Difference | 60.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | 21.47% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 17.77 and a Piotroski F-Score of 6.
| Altman Z-Score | 17.77 |
| Piotroski F-Score | 6 |
